echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China's research and development of new crown recombinant protein vaccine three-dose program in many places, one after another

    China's research and development of new crown recombinant protein vaccine three-dose program in many places, one after another

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    China's research and development of new crown recombinant protein vaccine three-dose program in many places, one after another
    China's research and development of the new crown recombinant protein vaccine three-dose program successively inoculated in many places China's research and development of the new crown recombinant protein vaccine three-dose program in many places successively vaccinated

    China news agency, Beijing, May 28 (Reporter Sun Zifa) - Reporter on the 28th from China Ke Xueyuan Institute of Microbiology ( Zhong Keyuan microorganisms) was informed by the company of the joint research and development with a three-dose schedule, the first approved clinical International The new coronavirus recombinant subunit protein vaccine used, the first injection was started in Beijing on the 27th.


    Academy of Sciences Zhong ASTRI ASTRI

    So far, the new crown recombinant protein vaccine, one of China’s five vaccine technology routes, has been approved for emergency use in China in mid-March and has been successively used in Anhui, Zhejiang, Jiangsu, Shandong, Guizhou, Hubei, Henan, Beijing and other provinces.


    The new crown recombinant protein vaccine (Chi Parkway was) by the Zhong Keyuan microorganisms high-fu Academy of team research and joint research and development company in Anhui Chi Dragon Coma, fourth paragraph is China approved the emergency use of a new vaccine crown.


    Zhong ASTRI ASTRI academicians

    Zhong Keyuan microorganisms, the new crown recombinant protein vaccine with three-dose schedule, its technical principles and have been used for very mature hepatitis B vaccine similar.


    Zhong ASTRI ASTRI

    A phase II clinical trial of the vaccine in adults aged 18-59 showed that after the subjects received 2 doses, the neutralizing antibody positive conversion rate reached 83%, and after the subjects received 3 doses, the neutralizing antibody positive conversion rate Up to 97%.


    Zhong Keyuan microorganisms In particular, the new crown recombinant protein vaccine produced using CHO production of recombinant proteins, do not need high-level biosafety laboratory production workshop, the production process is stable and reliable, quick implementation of large-scale industrial production, significantly reducing the cost of vaccine production, And it is convenient to store and transport.


    Zhong ASTRI ASTRI

    It is understood, May 3, Beijing successfully off the assembly line production of the first batch of the new crown recombinant protein vaccine, May 27, from the vaccine research and development base Zhong Keyuan part of researchers microorganisms in " Zhong Keyuan vaccination special" Inject the first shot of its three-shot procedure.


    Zhong ASTRI ASTRI Zhong ASTRI ASTRI aspx?id=3570" target="_blank" style="color:#ba1413">poly Jiaoxin Guan pneumonia epidemic
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.